6 studies found for:    14724302 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
Conditions: Coronary Disease;   Angina, Unstable
Interventions: Drug: Abciximab;   Drug: Placebo
2 Completed Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)
Conditions: Coronary Artery Disease;   Atherosclerosis;   Diabetes Mellitus;   Metabolic Syndrome X
Intervention: Procedure: blood samples
3 Completed Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)
Condition: Myocardial Infarction
Interventions: Drug: Abciximab;   Other: Placebo Heparin Sodium
4 Completed Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)
Conditions: Coronary Disease;   Angina Pectoris
Interventions: Drug: Bivalirudin;   Drug: Un-fractionated heparin
5 Completed 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
Condition: Coronary Disease
Intervention: Drug: Clopidogrel
6 Completed Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI
Condition: Coronary Artery Disease
Intervention: Drug: unfractionated heparin

Indicates status has not been verified in more than two years